{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T21:52:28Z","timestamp":1784929948250,"version":"3.55.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1016\/j.medcli.2012.10.028","type":"journal-article","created":{"date-parts":[[2013,2,22]],"date-time":"2013-02-22T04:46:57Z","timestamp":1361508417000},"page":"95-99","source":"Crossref","is-referenced-by-count":10,"title":["Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors"],"prefix":"10.1016","volume":"141","author":[{"given":"Silvia","family":"Marc\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lurdes","family":"Zamora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Cabez\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blanca","family":"Xicoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concha","family":"Boqu\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristalina","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Grau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9-Tom\u00e1s","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Fern\u00e1ndez de Sevilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep-Maria","family":"Ribera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evarist","family":"Feliu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuensanta","family":"Mill\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medcli.2012.10.028_bib0005","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/300765a0","article-title":"A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia","volume":"5894","author":"de Klein","year":"1982","journal-title":"Nature"},{"key":"10.1016\/j.medcli.2012.10.028_bib0010","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/299747a0","article-title":"Chromosomal localization of human cellular homologues of two viral oncogenes","volume":"5885","author":"Heisterkamp","year":"1982","journal-title":"Nature"},{"key":"10.1016\/j.medcli.2012.10.028_bib0015","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/leu.2010.16","article-title":"Chronic myeloid leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 activity","volume":"4","author":"Engler","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.medcli.2012.10.028_bib0020","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood-2008-03-144790","article-title":"Molecular biology of bcr-abl1-positive chronic myeloid leukemia","volume":"8","author":"Quintas-Cardama","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2012.10.028_bib0025","doi-asserted-by":"crossref","first-page":"7519","DOI":"10.1158\/1078-0432.CCR-09-1068","article-title":"Mechanisms of resistance to imatinib and second-generation tyrosine inhibitors in chronic myeloid leukemia","volume":"24","author":"Milojkovic","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.medcli.2012.10.028_bib0030","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","article-title":"Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome","volume":"14","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2012.10.028_bib0035","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"6","author":"Baccarani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2012.10.028_bib0040","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"1","author":"Hughes","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2012.10.028_bib0045","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.1182\/blood-2008-06-162388","article-title":"European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor","volume":"12","author":"Marin","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2012.10.028_bib0050","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","article-title":"Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia","volume":"7","author":"O\u2019Hare","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2012.10.028_bib0055","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia","volume":"2","author":"Shah","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1016\/j.medcli.2012.10.028_bib0060","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","article-title":"Overriding imatinib resistance with a novel ABL kinase inhibitor","volume":"5682","author":"Shah","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.medcli.2012.10.028_bib0065","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl","volume":"2","author":"Weisberg","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.medcli.2012.10.028_bib0070","article-title":"Organizaci\u00f3n Mundial de la Salud and Asociaci\u00f3n Internacional de Investigaci\u00f3n sobre el Cancer","author":"Swerdlow","year":"2008"},{"key":"10.1016\/j.medcli.2012.10.028_bib0075","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","article-title":"Standardization and quality control studies of \u2018real-time\u2019 quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia\u2014a Europe Against Cancer program","volume":"12","author":"Gabert","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.medcli.2012.10.028_bib0080","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/sj.leu.2404137","article-title":"The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib","volume":"4","author":"Khorashad","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.medcli.2012.10.028_bib0085","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1200\/JCO.2010.31.3619","article-title":"Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia","volume":"5","author":"Cortes","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.medcli.2012.10.028_bib0090","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","article-title":"Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia","volume":"11","author":"Apperley","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.medcli.2012.10.028_bib0095","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1182\/asheducation-2009.1.461","article-title":"Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance","author":"Bixby","year":"2009","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.medcli.2012.10.028_bib0100","doi-asserted-by":"crossref","first-page":"4944","DOI":"10.1182\/blood-2009-04-214221","article-title":"Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations","volume":"24","author":"Muller","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2012.10.028_bib0105","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1756-8722-3-47","article-title":"First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib","author":"Wei","year":"2010","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.medcli.2012.10.028_bib0110","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1373\/clinchem.2009.133843","article-title":"Detection of drug-resistant clones in chronic myelogenous leukemia patients during dasatinib and nilotinib treatment","volume":"3","author":"Gruber","year":"2010","journal-title":"Clin Chem"},{"key":"10.1016\/j.medcli.2012.10.028_bib0115","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.3109\/10428191003729741","article-title":"Mutations in ABL kinase domain are associated with inferior progression-free survival","volume":"6","author":"Sharma","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.medcli.2012.10.028_bib0120","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/leu.2008.84","article-title":"Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib","volume":"6","author":"Hochhaus","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.medcli.2012.10.028_bib0125","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1182\/blood-2010-03-277152","article-title":"Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results","volume":"4","author":"Kantarjian","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2012.10.028_bib0130","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1200\/JCO.2008.19.8853","article-title":"Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR\/ABL mutants","volume":"3","author":"Redaelli","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.medcli.2012.10.028_bib0135","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1111\/j.1365-2362.2010.02328.x","article-title":"Standard treatment of Ph+ CML in 2010: how, when and where not to use what BCR\/ABL1 kinase inhibitor?","volume":"10","author":"Valent","year":"2010","journal-title":"Eur J Clin Invest"}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775313000146?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775313000146?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,18]],"date-time":"2018-10-18T09:31:09Z","timestamp":1539855069000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775313000146"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["S0025775313000146"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2012.10.028","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2013,8]]}}}